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LIVER TRANSPLANTATION IN POSITIVE CYTOTOXIC CROSSMATCH CASES USING FK506, HIGH-DOSE 
STEROIDS, AND PROSTAGLANDIN Ell 
Although the liver is resistant. to antibody-mediated rejection 
(1), a significant adverse effect has been reported of its trans-
plantation into recipients with preformed cytotoxic antibodies 
(2). We report here a strategy that appears to convert the 
prognosis in such potentially disadvantaged patients to essen-
tially the same if not better than that in conventionally treated 
crossmatch-negative recipients. 
The crossmatch status was determined with recipient sera 
treated with dithiothreitol (DTT) (3). Four cohorts of adult 
liver recipients were studied. In all, intravenous FK506 was 
started with doses of 0.075 to 0.15 mg/kg/day, and converted 
to oral dosing after resumption of diet. Treatment was guided 
by plasma FK5061evels (target approximately 1 ng/ml), toxic-
ity (primarily renal), the clinical status of the patient, and the 
quality of postoperative liver function (4). The 4 study groups 
(Table 1) differed in the cytotoxic crossmatch state (negative 
in group 1 only), the use of prostaglandin EI (group 4 only), 
and the prophylactic use of methylprednisolone (MP). Low-
dose MP was with 20 mg/day starting on the day of trans plan-
tation (most of group 1 and all of group 2). High-dose MP was 
with 1 g Lv. during operation, followed by a "burst" with 200 
mg the first day and daily decreases of 40 mg until 20 mg/day 
was reached on the 6th day if the course was uneventful (groups 
3 and 4). In group 4, i.v. PGE, (Prostin VR) was started after 
completion of the operation with 0.2 ILg/kg/hr and gradually 
increased to 0.6 ILg/kg/hr if tolerated without cardiovascular 
instability. One of the 14 patients in group 4 had transient 
hypotension. There were no other side effects of PGEh which 
was stopped without weaning when the patients resumed diet 
after 5-7 days. 
The crossmatch positive cases in groups 2-4 were consecu-
tive, with no omissions. The incidences of hepatic malignancy, 
high UNOS urgency scores (50-78% III or IV), and cytotoxic 
titers> 1:8 were similar in the cytotoxic groups 2-4. Females 
were disproportionately represented in all of the crossmatch-
1 This work was -supported by Research Grants from the Veterans 
Administration and by Project Grant DK 29961 from the National 
Institutes of Health, Bethesda, MD. 
positive groups compared with crossmatch-negative controls. 
In the crossmatch-positive .cases, the outcome was remarkably 
different according to treatment (Table 1). With high-dose 
steroid therapy (group 3), the unacceptably high early and 
delayed graft loss seen with low-dose steroid therapy (group 2) 
was reduced by two-thirds. Graft loss was reduced further if 
PGE1 was added to the high-dose steroid regimen (group 4). 
The only death in the 14 patients of group 4 was caused by a 
biliary leak and subhepatic infection in a patient whose native 
gall bladder had empyema. The favorable course of the group 4 
recipients relative even to group 3 and especially group 2 
patients was reflected by an improvement in the perioperative 
renal function (Fig. 1), and superior postoperative liver function 
(Fig. 2). 
The superior renal function in the liver recipients of group 4 
was noteworthy. It is possible the PGE1 specifically protects 
the kidneys from FK506 nephrotoxicity by a mechanism similar 
to that described by Makowka et a1. (5) for cyc1osporine. 
However, protection of the liver graft from antibody-mediated 
rejection and consequent avoidance of prerenal complications 
may have been a significant or even more important factor. 
The pathogenesis of hyperacute rejection of kidney grafts, 
- TABLE 1. T lymphocytotoxic crossmatch state 
Group 1 (n=216) 2 (n=28) 3 (n=12) 4 (n=14) 
Crossmatch Negative Positive Positive Positive 
Methyl prednisolone Variable Low High High 
PGE1 No No No Yes 
Hepatic malignancy 7.4% 3.6% 7.1% 8.3% 
Male/female 130/86 12/16 0/12 3/11 
High-titer (>1:8) 14 9 9 
Survival (6 months)· 
Patient 90.5% 71.4%b 92.3% 92.9% 
Graft 84.8% 60.7%' 83.3% 92.9% 
Median follow-upd 454 d 446 d 320d 240d 
a Actual survival. 
b Group 1 VB. 2, P=0.0006. 
, Group 2 vs. 3, P=0.125; group 2 VS. 4, P=O.03. 
d Follow-up of 6 to 25 months. 
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FIGURE 1. First-week FK506 doses and plasma concentrations and 
serum creatinine (Cr) in crossmatch-positive liver recipients (groups 2, 
3, 4). (Cr)-group 2 vs. 3 P<O.OOOl, 2 VS. 4 P<O.OOOl, 3 vs. 4 = P = 
and the much slower manifestations of antibody-mediated re-
jection seen in liver grafts are not fully understood (6). What-
ever the mechanisms, it has been known since the earliest work 
of Dempster (7) that intense vasoconstriction occurs of the 
graft microvasculature (8). PGE] treatment added to FK506 
and high doses of steroids could have ameliorated this conse-
quence, aside from its inherent immunosuppressive (9) and 
cytoprotective (10) qualities. Amelioration by PGE] of humoral 
rejection has not been reported clinically, but there have been 
clues of its potential value in xenograft transplant models that 
have heterospecific antibody barriers, including cat-to-dog (1 I), 
hamster-to-rat (12), and pig-to-dog (13). 
High-dose prednisone in conjunction with FK506 but without 
PGE] also was effective. The steroid mitigation of humoral 
rejection presumably was by different pathways although both 
glucocorticoids and PGE suppress cytokines (14, 15). Accurate 
delineation of these drug actions and interactions will be of the 
greatest interest in providing clues for other therapeutic im-
provements. 
At a practical level, the experience reported herein indicates 
not only the feasibility but also the surprising ease with which 
the liver can be transplanted to sensitized recipients. If opti-
mum therapy is given, a policy of excluding patients with widely 
reacting cytotoxic antibodies from candidacy for liver trans-
plantation would seem unwarranted. The results in the high-
0.007. FK506 dose-2 vs. 3 P<O.OOOl, 2 vs. 4 P<0.0004, 3 VS. 4 = P = 
0.2. The average plasma FK506 value in group 2 was significantly 
higher than in groups 3 and 4 (P = 0.0004). Wilcoxon rank-sum test. 
dose steroid-PGE1 group 4 were at least as good as in the cases 
with negative crossmatches. Whether all liver transplantations, 
including those with crossmatch-negative donors should be 
given this treatment deserves consideration. PGE] already has 
been used in this way in cyclosporine-based drug cocktails for 
crossmatch-negative kidney transplantation (16). 
There wer ... no obvious artifacts that would undermine these 
conclusions, such as the use in later cases of a different titer 
cutoff for a positive-crossmatch reading. About the same per-
centage of titers greater than 1:8 were in groups 2-4, but the 
highest positive titer was not measured systematically at the 
time of the case accrual. In 6 subsequent patients who were 
given the optimal recommended treatment and who had titers 
equal to or greater than 1:256, only 1 had a humoral rejection. 
This was a female patient with a titer of 1:1024 who required 
retransplantation 2 days after primary graft nonfunction, using 
a crossmatch-positive donor liver (titer 1:2) on the second 
occasion. She is well 4 months later. 
The influence of titers, different sensitization schedules, and 
the nature of the antibody upon humoral rejection of the liver 
in rats has been described elsewhere.4 These experimental 
studies, combined with our clinical experience herein reported, 
4 Furuya T, Murase N, Nakamura K, et a1. Preformed lymphocyto-
toxic antibodies: the effects of Ig class, titer and specificity on liver 
versus heart allografts. (Submitted for publication.) 
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FIGURE 2. Serum total bilirubin (1st month) and serum GOT levels 
(2 weeks) in crossmatch-positive liver recipients. Bilirubin in first 
week-group 2 vs. 3 P = 0.007, 2 vs. 4 P<O.Ol, 3 vs. 4 P=0.36. SGOT 
in first week-group 2 vs. 3 P=O.36, 2 vs. 4 P<0.02, 3 vs. 4 P=0.38. 
Wilcoxon rank-sum test. 
have led to our present policy of not delaying urgently needed 
liver transplantation in order to search for a more appropriately 
crossmatched donor. 
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